Is RKLB Stock A Buy Or A High-Beta Trap?

The multiple rests on a launch vehicle that has yet to fly and an acquisition that has yet to close, while most of the revenue arriving today comes from satellites.

Rocket Lab (RKLB) trades near $66, about 56% below its 52-week high, and still carries roughly 54 times trailing sales against 3.3 for the S&P 500. That multiple is not a verdict on the business the company ran in Q2 2026. It rests on a rocket that has not flown and an acquisition that has not closed, and on Space Systems holding its growth in the meantime.

Space Systems, Not Rockets, Delivered The Record Quarter

The business behind that multiple is largely a satellite maker. Of the record $234 million of revenue in Q2 2026, up 62% year over year, $189.5 million came from Space Systems, which builds satellites and their components, against $44.6 million from Launch Services. Trailing twelve-month revenue is about $0.8 billion. Electron flew its 93rd mission in August, carrying an Earth-imaging satellite for iQPS, but launch remains the smaller of Rocket Lab’s two segments.

Neutron Has Not Flown And Iridium Has Not Closed

Neutron, the medium-lift vehicle that would take Rocket Lab beyond small launch, is still coming together. Neutron’s production schedule points to a target delivery to the pad in Q4 2026, and the company concedes the window for a launch before the end of 2026 is narrowing. Iridium is the other half: 66 satellites and more than 2.5 million subscribers delivering more than $870 million of revenue over the past year, more than Rocket Lab recorded itself over the trailing twelve months. That deal is not expected to close until mid-2027, and management calls the business it is buying relatively slow-growing. Meanwhile the order book holds: backlog of about $2.36 billion at the end of Q2 2026, and a first order for Flatellite, the spacecraft designed for rapid production.

The Wait Is Being Funded Out Of Cash And Stock Sales

None of the waiting is free. The operating margin is deeply negative at -29.1%, against 18.4% for the S&P 500. Non-GAAP free cash flow was negative $110.1 million in Q2 2026 after negative $77.4 million in Q1 2026, and management expects cash consumption to stay elevated while additional Neutron vehicles are built and longer-lead parts for its SDA programs are procured. The cash and securities balance finished Q2 2026 near $2.4 billion, though the $1.08 billion of stock sold that quarter is intended for acquisitions, Iridium among them. Businesses that fund their own growth out of operating cash are a different proposition from Rocket Lab today, and they are what the Trefis High Quality Portfolio holds.

First Flight And The Closing Are The Dates That Decide This

Management ties the inflection in cash burn to Neutron’s first successful test flight, though cash flow positivity remains 18 to 24 months beyond that milestone. Still, the valuation premium becomes easier to defend if Neutron flies, Space Systems maintains its recent pace, and Iridium closes to shoulder the multiple. It gets harder if first flight slips and the price must ride on trailing revenue for longer. The repricing runs fast both ways: the stock is up 40.2% over the past twelve months and down 55.9% over the trailing three, against 2.1% for the S&P 500 over those same three months, and it fell 70% in the 2022 inflation shock against 24% for the index. Those pieces sit in one view on the five-factor stock scorecard.

Buy It Or Fear It, How Much Of It Should You Own?

Whichever way the call lands, the bigger question is how much of any single stock belongs in a portfolio at all. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.